Spain Psoriasis Treatment Market Overview, 2031

The treatment for psoriasis in Spain is heavily influenced by the publicly funded National Health System, which grants extensive access to dermatological services and advanced treatment options through a decentralized regional system. In the last ten years, the rise in biologic treatments has been substantial as dermatologists in Spain implement targeted therapies for moderate to severe cases of psoriasis and psoriatic arthritis, adhering to European clinical recommendations. Treatment protocols are created by regional health authorities and hospital committees, aligning with the national dermatology society's guidelines, which advocate for a gradual treatment strategy starting with topical treatments and phototherapy, progressing to systemic medications, and eventually biologics when standard therapies do not succeed. This systematic approach ensures cost-effective healthcare while facilitating access to advanced therapies for those who qualify. Dermatology departments within hospitals are the central points for starting biologic treatments, monitoring patients, and managing long-term disease care. Multidisciplinary teams, consisting of dermatologists, pharmacists, and specialized nurses, work together to create treatment strategies, supervise safety, and confirm compliance with regional financial support criteria. Furthermore, Spanish dermatological research groups and national databases have played a role in generating real-world evidence that endorses the safety and efficacy of biologic treatments, fostering wider acceptance in clinical practice. Despite the rise in biologic usage, disparities in healthcare funding and formulary choices across different regions can lead to inconsistencies in access and prescription trends throughout autonomous communities. Still, the growing availability of innovative biologics and the establishment of standardized regional guidelines have enhanced treatment results and decreased disease impact for numerous patients in Spain. The environment for managing psoriasis in Spain reflects a blend of fair access within a public healthcare framework, organized regional decision-making, and advancing clinical skills that continue to promote biologic use and modernize dermatological care throughout the nation.

According to the research report, " Spain Psoriasis Treatment Market Overview, 2031," published by Bonafide Research, the Spain Psoriasis Treatment market is anticipated to grow at more than 10.31% CAGR from 2026 to 2031. The psoriasis sector in Spain is steadily expanding due to the integration of biosimilars, the growth of digital healthcare, and changing hospital procurement strategies. Biosimilars have emerged as a crucial part of Spain’s efforts to control costs, enabling regional health systems and hospitals to lower drug spending while enhancing patient access to advanced biologic treatments. The processes of competitive tendering and centralized purchasing agreements shape the way prescriptions are written, often promoting dermatologists to choose biosimilars as the primary biologic treatment when clinically suitable. These purchasing strategies have fostered market competitiveness and have led to more sustainable healthcare expenses without sacrificing the effectiveness of treatments. The use of teledermatology saw a notable increase following the COVID-19 pandemic, establishing itself as an essential resource for patient triage, follow-up visits, and remote monitoring of treatment progress. Virtual healthcare has proven particularly useful for individuals in rural or lacking access areas who encounter difficulties traveling to specialist clinics. Many hospitals are now merging teledermatology platforms with electronic health records, which allows for remote evaluations of skin conditions and encourages cooperation between primary care doctors and dermatologists. This shift to digital services has improved the rates of early diagnoses, shortened waiting times for specialized appointments, and bolstered the continuity of care for patients with chronic psoriasis. Hospital purchasing groups and local healthcare organizations are still influencing the market for psoriasis treatments in Spain by focusing on therapies that are cost-effective and assessing their clinical value using pharmacoeconomic studies.

Spain psoriasis treatment market by type is divided into plaque psoriasis, psoriatic arthritis and others. The prevalence of psoriasis in Spain aligns with broader trends in Europe, affecting around 2–3% of the population. Plaque psoriasis is the most prevalent form, making up nearly 80–90% of confirmed cases. This type causes the majority of visits to dermatology clinics, prescription rates, and healthcare expenditures since patients often need ongoing treatment and management. The dermatology guidelines in Spain advocate for early assessments of severity and established referral processes from primary healthcare to specialized dermatology services. Cases of moderate-to-severe plaque psoriasis are typically treated in specialized outpatient centers, where systemic treatments or biologic options are initiated as per regional protocols. The rise of biologic treatments and increased clinical awareness have led to enhanced disease management and improved quality of life for patients with chronic plaque conditions in Spain. Psoriatic arthritis is a significant secondary condition, impacting many individuals with psoriasis in Spain. This group requires collaborative care between dermatologists and rheumatologists, considering the potential for progressive joint damage and disability. Initiatives for early detection backed by Spanish medical organizations promote the screening of joint-related symptoms during dermatology appointments. Patients suffering from psoriatic arthritis frequently need advanced treatments, especially biologics, leading to substantial expenditure on high-cost therapies within Spain's public healthcare framework. Multidisciplinary clinics in larger hospitals are crucial for handling complicated cases and enhancing long-term health outcomes for these patients. The others category encompasses guttate, pustular, erythrodermic, and inverse psoriasis. Although these types represent a minor percentage of cases, their clinical complexity may necessitate hospitalization during severe episodes or intensive treatments. Rare conditions like generalized pustular psoriasis require specialized care and diligent monitoring.

Spain psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others. The treatment strategy for psoriasis in Spain reflects a step-by-step approach, following European dermatological guidelines and local healthcare policies. Topical treatments are still the main option for mild cases, including corticosteroids, vitamin D derivatives, and combination products widely prescribed by both dermatologists and general practitioners. These treatments capture a significant portion of prescription activity due to their availability and inclusion in public health funding schemes. Phototherapy, especially narrowband UV-B, remains a popular choice in hospital dermatology units and specialized outpatient clinics, serving as an affordable intermediate treatment option for moderate cases. Systemic treatments like methotrexate, ciclosporin, acitretin, and oral small-molecule medications are essential choices for managing moderate to severe psoriasis, particularly when topical treatments and phototherapy are not effective. In Spain, reimbursement policies often mandate that patients show an insufficient response to standard systemic therapies before they can receive biologic treatments, which keeps these options important in medical practice. Nevertheless, biologics are the fastest-growing category of treatments, fueled by advancing clinical knowledge, better patient results, and a rising availability of biosimilars. Dermatology departments in hospitals typically oversee the initiation and monitoring of biologics due to safety and regulatory obligations. Interleukin-targeted therapies and TNF inhibitors are commonly prescribed for both severe plaque psoriasis and psoriatic arthritis. The others group includes new treatments like targeted oral inhibitors, combination therapy, and personalized treatment plans for patients with al health issues or resistant diseases. Spain's involvement in European clinical trials and the increasing use of biosimilars continue to enhance treatment advancements. The categorization of treatments illustrates a shift from easily accessible topical and phototherapy options to systemic and advanced biologic therapies for severe cases, carefully balancing effectiveness and cost management within Spain's public healthcare framework.

Spain psoriasis treatment market by distribution channel is divided into hospital pharmacies, retail pharmacies and e-commerce. The distribution of psoriasis medications in Spain is greatly shaped by its publicly funded healthcare system and its hospital-focused approach for advanced treatments. Hospital pharmacies are the main providers of biologic medications and expensive systemic therapies, particularly during the start of treatment and for patients with severe forms of the disease. Dermatological departments in hospitals work closely with pharmacists to manage logistics related to cold storage, patient education, training for injections, and monitoring treatment. The processes for regional procurement and centralized purchasing agreements also affect how medications are distributed in hospital pharmacies, promoting cost-effective use of drugs and broad adoption of biosimilars. Retail pharmacies serve as the main source for topical treatments, oral systemic drugs, and ongoing prescriptions after patients stabilize their conditions. Spain has a large network of community pharmacies that offer easy access to medications, patient advice, and help with adherence to treatment. Pharmacists play a crucial role in collaborating with doctors to ensure patients have a constant supply of treatments and guide patients through the public healthcare system. Retail pharmacies also provide skincare products and maintenance therapies, making them vital for managing psoriasis over the long term beyond hospital settings. E-commerce and online pharmacy services have been steadily rising, especially after the boost in telemedicine use following the COVID-19 pandemic. Licensed online pharmacies allow for electronic prescriptions, deliver maintenance medications to homes, and improve access for patients in rural or less served areas. While biologics are still mainly provided through hospital networks due to regulatory and monitoring needs, online pharmacy services are increasingly being linked with teledermatology and remote patient tracking initiatives.



Considered in this report
* Historic Year: 2020
* Base year: 2025
* Estimated year: 2026
* Forecast year: 2031

Aspects covered in this report
* Psoriasis Treatment Market with its value and forecast along with its segments
* Various drivers and challenges
* On-going trends and developments
* Top profiled companies
* Strategic recommendation

By Type
Plaque Psoriasis
Psoriatic Arthritis
Others

By Treatment Type
Biologics Drugs
Systemic Drugs
Topical Drugs
Phototherapy
Others

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
e-Commerce